Peptide targeting of platinum anti-cancer drugs

Bioconjugate Chemistry

Volumn 20, Issue 10, 2009, Pages 1869-1878

  Ndinguri, Margaret W ^a   Solipuram, Rajasree ^b   Gambrell, Robert P ^a   Aggarwal, Sita ^b   Hammer, Robert P ^a,c  

^a LOUISIANA STATE UNIVERSITY   (United States)

^b PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^c New England Peptide   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DEATH; CONTROLLED DRUG DELIVERY; DRUG INTERACTIONS; FLUORESCENCE MICROSCOPY; PLATINUM COMPOUNDS; TARGETED DRUG DELIVERY;

ANTICANCER DRUG; CARBOPLATIN; CELL-BE; CELL/B.E; CELL/BE; MALONATES; PEGYLATED; PLATINUM ANTICANCER DRUGS; SIDE EFFECT; SYNTHESISED;

PEPTIDES;

CARBOPLATIN; CASPASE 3; CASPASE 7; CYSTEINYLASPARGINYLGLYCYLARGINYLCYSTEIN; DI TERT BUTYL 2 (3 AMINOPROPYL)MALONATE; DI TERT BUTYL 2 (3 PHTHALIMIDOPROPYL)MALONATE; DI TERT BUTYL 2 [3 (4 CARBOXYBUTANAMIDO)PROPYL]MALONATE; DOXORUBICIN; MALONIC ACID DERIVATIVE; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; APOPTOSIS; ARTICLE; CANCER CELL; CELL VIABILITY; COMPLEX FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DNA FRAGMENTATION; DRUG CONJUGATION; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MOLECULAR WEIGHT;

ANTIGENS, CD13; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARBOPLATIN; CASPASES; CELL LINE, TUMOR; DNA FRAGMENTATION; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MALE; MOLECULAR TARGETED THERAPY; OLIGOPEPTIDES; PLATINUM;

EID: 70350641403     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc900065r     Document Type: Article

References (67)

1. Wang, D., and Lippard, S. J. (2005) Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discovery 4, 307-320. (Pubitemid 41130944)
2. Reedijk, J. (1996) Improved understanding in platinum antitumor chemistry. Chem. Commun. (Cambridge) 801-806.
3. Shipp, M., and Look, T. (1993) Hematopoietic differentiation antigens that are membrane-associated enzymes: Cutting is the key! Blood 82, 1052-1070. (Pubitemid 23253976)
4. Jamieson, E., and Lippard, S. (1999) Structure, recognition, and processing of cisplatin-DNA adducts. Chem. Rev. 99, 2467-2498.
5. Hamelers, I. H. L., Van Loenen, E., Staffhorst, R. W. H. M., De Kruijff, B., and De Kroon, A. I. P. M. (2006) Carboplatin nanocapsules: a highly cytotoxic, phospholipid-based formulation of carboplatin. Mol. Cancer Ther. 5, 2007-2012.
6. Sood, P., Thurmond, K. B., II, Jacob, J. E., Waller, L. K., Silva, G. O., Stewart, D. R., and Nowotnik, D. P. (2006) Synthesis and characterization of AP5346, a novel polymer-linked diaminocyclohexyl platinum chemotherapeutic agent. Bioconjugate Chem. 17, 1270-1279. (Pubitemid 44455337)
7. Kelland, L. R., Murrer, B. A., Abel, G., Giandomenico, C. M., Mistry, P., and Harrap, K. R. (1992) Ammine/amine platinum(IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res. 52, 822-828.
8. Cubeddu, L. X., Hoffmann, I. S., Fuenmayor, N. T., and Finn, A. L. (1990) Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N. Engl. J.Med. 322, 810-816.
9. Ghezzi, A., Aceto, M., Cassino, C., Gabano, E., and Osella, D. (2004) Uptake of antitumor platinum(II) complexes by cancer cells, assayed by inductively coupled plasma mass spectrometry (ICP-MS). J. Inorg. Biochem. 98, 73-78. (Pubitemid 37495012)
10. Katano, K., Kondo, A., Safaei, R., Holzer, A., Samimi, G., Mishima, M., Kuo, Y.-M., Rochdi, M., and Howell, S. B. (2002) Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Res. 62, 6559-6565. (Pubitemid 35364122)
11. van Zutphen, S., and Reedijk, J. (2005) Targeting platinum anti-tumour drugs: Overview of strategies employed to reduce systemic toxicity. Coord. Chem. Rev. 249, 2845-2853.
12. Galanski, M., and Keppler, B. K. (2007) Searching for the magic bullet: anticancer platinum drugs which can be accumulated or activated in the tumor tissue. Anti-Cancer Agents Med. Chem. 7, 55-73. (Pubitemid 46062405)
13. Pasqualini, R., Koivunen, E., and Ruoslahti, E. (1995) A peptide isolated from phage display libraries is a structural and functional mimic of an RGD-binding site on integrins. J. Cell Biol. 130, 1189-1196.
14. Haubner, R., Wester, H.-J., Burkhart, F., Senekowitsch-Schmidtke, R., Weber, W., Goodman, S., Kessler, H., and Schwaiger, M. (2001) Glycosylated RGD-containing peptides: Tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J. Nucl. Med. 42, 326-336. (Pubitemid 32150525)
15. Bhagwat, S., Lahdenranta, J., Giordano, R., Arap, W., Pasqualini, R., and Shapiro, L. (2001) CD13/APN is activated by angiogenic signals and is essential for capillary tube formation. Blood 97, 652-659. (Pubitemid 32113397)
16. Hansel, W., Enright, F., and Leuschner, C. (2007) Destruction of breast cancers and their metastases by lytic peptide conjugates in vitro and in vivo. Mol. Cell. Endocrinol. 260-262, 183-189. (Pubitemid 44792362)
17. Leuschner, C., Kumar, C. S. S. R., Hansel, W., and Hormes, J. (2005) Targeting breast cancer cells and their metastases through luteinizing hormone releasing hormone (LHRH) receptors using magnetic nanoparticles. J. Biomed. Nanotechnol. 1, 229-233.
18. Nagy, A., and Schally, A. V. (2002) Cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH): a new approach to targeted chemotherapy. Drugs Future 27, 359-370. (Pubitemid 34639718)
19. Schally, A. V., and Nagy, A. (1999) Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur. J. Endocrinol. 141, 1-14.
20. Schally, A. V., and Nagy, A. (2003) New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin. Life Sci. 72, 2305-2320.
21. Pasqualini, R., Koivunen, E., Kain, R., Lahdenranta, J., Sakamoto, M., Stryhn, A., Ashmun, R., Shapiro, L., Arap, W., and Ruoslahti, E. (2000) Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res. 60, 722-727. (Pubitemid 30094573)
22. Arap, W., Pasqualini, R., and Ruoslahti, E. (1998) Cancer treatment by targeted drug delivery to tumor vasculature in a mouse. Science 279, 377-380. (Pubitemid 28063372)
23. Anizon, F., Boyle, T., Fisher, J., and Kocienski, P. (2002) Synthesis and characterisation of a doxorubicin-CNGRC peptide conjugate that target tumor vasculature. Synthesis 18, 2733-2736. (Pubitemid 36034435)
24. Zhang, Z., Hatta, H., Tanabe, K., and Nishimoto, S.-i. (2005) A new class of 5-fluoro-2-deoxyuridine prodrugs conjugated with atumor-homing cyclic peptide CNGRC by ester linkers: Synthesis, reactivity, and tumor-cell-selective cytotoxicity. Pharm. Res. 22, 381-389.
25. Hanahan, D., and Folkman, J. (1996) Patterns and emerging mechanisms review of the angiogenic switch during tumorigenesis. Cell 86, 353-364. (Pubitemid 26272076)
26. Bhagwat, S., Petrovic, N., Okamoto, Y., and Shapiro, L. (2003) The angiogenic regulator CD13/APN is a transcriptional target of Ras signaling pathways in endothelial morphogenesis. Blood 101, 1818-1826. (Pubitemid 36237579)
27. Birkenkamp-Demtroder, K., Christensen, L. L., Olesen, S. H., Frederiksen, C. M., Laiho, P., Aaltonen, L. A., Laurberg, S., Sorensen, F. B., Hagemann, R., and Orntoft, T. F. (2002) Gene expression in colorectal cancer. Cancer Res. 62, 4352-4363.
28. Curnis, F., Arrigoni, G., Sacchi, A., Fischetti, L., Arap, W., Pasqualini, R., and Corti, A. (2002) Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res. 62, 867-874. (Pubitemid 34126966)
29. Ikeda, N., Nakajima, Y., Tokuhara, T., Hattori, N., Sho, M., Kanehiro, H., and Miyake, M. (2003) Clinical significance of aminopeptidase N/CD13 expression in human pancreatic carcinoma. Cancer Res. 9, 1503-1508. (Pubitemid 36418408)
30. Shepherd, F., and Sridhar, S. (2003) Angiogenesis inhibitors under study for the treatment of lung cancer. Lung Cancer 41, 63-72. (Pubitemid 36818997)
31. Giguere, C. M., Bauman, N. M., and Smith, R., J. H. (2002) New treatment options for lymphangioma in infants and children. Ann. Otol. Rhinol. Laryngol. 111, 1066-1075.
32. Hashida, H., Takabayashi, A., Kanai, M., Adachi, M., Kondo, K., Kohno, N., Yamaoka, Y., and Miyake, M. (2002) Aminopeptidase N is involved in cell motility and angiogenesis: its clinical significance in human colon cancer. Gastroenterology 122, 376-386. (Pubitemid 34116989)
33. Albericio, F., Cases, M., Alsina, J., Triolo, S. A., Carpino, L. A., and Kates, S. A. (1997) On the use of PyAOP, a phosphonium salt derived from HOAt, in solid-phase peptide synthesis. Tetrahedron Lett. 38, 4853-4856. (Pubitemid 27277980)
34. Aronov, O., Horowitz, A., Gabizon, A., and Gibson, D. (2003) Folate-targeted PEG as a potential carrier for carboplatin analogs. Synthesis and in vitro studies. Bioconjugate Chem. 14, 563-574. (Pubitemid 36597366)
35. Berners-Price, S. J., Frenkiel, T. A., Frey, U., Ranford, J. D., and Sadler, P. J. (1992) Hydrolysis products of cisplatin: pKa determinations via [1H, 15N] NMR spectroscopy. J. Chem. Soc., Chem. Commun 789-791.
36. Appleton, T. G., Hall, J. R., Ralph, S. F., and Thompson, C. S. M. (1989) NMR study of acid-base equilibria and other reactions of ammineplatinum complexes with aqua and hydroxo ligands. Inorg. Chem. 28, 1989-1993.
37. Appleton, T. G., Berry, R. D., Davis, C. A., Hall, J. R., and Kimlin, H. A. (1984) Reactions of platinum(II) aqua complexes. 1. Multinuclear (platinum-195, nitrogen-15, and phosphorus-31) NMR study of reactions between the cis-diamminediaquaplatinum(II) cation and the oxygen-donor ligands hydroxide, perchlorate, nitrate, sulfate, phosphate, and acetate. Inorg. Chem. 23, 3514-3521. (Pubitemid 15181147)
38. Palocsay, F. A., and Rund, J. V. (1969) Reaction between 1,10-phenanthroline and platinum(II) compounds. I. Reaction in aqueous solution. Inorg. Chem. 8, 524-528.
39. Basolo, F., Bailar, J. C., Jr., and Tarr, B. R. (1950) The stereochemistry of complex inorganic compounds. X. The stereoisomers of dichlorobis(ethylenediamine)platinum(IV) chloride. J. Am. Chem. Soc. 72, 2433-2438.
40. Aggarwal, S., Takada, Y., Singh, S., Myers, J. N., and Aggarwal, B. B. (2004) Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor-kB signaling. Int. J. Cancer 111, 679-692. (Pubitemid 39062889)
41. Alnemri, E. S., Livingston, D. J., Nicholson, D. W., Salvesen, G., Thornberry, N. A., Wong, W. W., and Yuan, J. (1996) Human ICE/CED-3 protease nomenclature. Cell 87, 171.
42. Dupere-Minier, G., Hamelin, C., Desharnais, P., and Bernier, J. (2004) Apoptotic volume decrease, pH acidification and chloride channel activation during apoptosis requires CD45 expression in HPB-ALL T cells. Apoptosis 9, 543-551. (Pubitemid 39158630)
43. Roberts, M. J., Bentley, M. D., and Harris, J. M. (2002) Chemistry for peptide and protein PEGylation. Adv. Drug Delivery Rev. 54, 459-476.
44. Veronese, F. M., and Pasut, G. (2005) PEGylation, successful approach to drug delivery. Drug Discovery Today 10, 1451-1458.
45. Esposito, P., Barbero, L., Caccia, P., Caliceti, P., D'Antonio, M., Piquet, G., and Veronese, F. M. (2003) PEGylation of growth hormone-releasing hormone (GRF) analogs. Adv. Drug Delivery Rev. 55, 1279-1291. (Pubitemid 37464562)
46. Milanesio, M., Monti, E., Gariboldi, M. B., Gabano, E., Ravera, M., and Osella, D. (2008) Trend in cytotoxic activity of a series of cis-[APtCl2] (A=ethylenediamine methylated at different positions) complexes. Inorg. Chim. Acta 361, 2803-2814.
47. Gabano, E., Colangelo, D., Ghezzi, A. R., and Osella, D. (2008) The influence of temperature on antiproliferative effects, cellular uptake and DNA platination of the clinically employed Pt(II)-drugs. J. Inorg. Biochem. 102, 629-635.
48. Bonetti, A., Apostoli, P., Zaninelli, M., Pavanel, F., Colombatti, M., Cetto, G. L., Franceschi, T., Sperotto, L., and Leone, R. (1996) Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy. Clin. Cancer Res. 2, 1829-1835. (Pubitemid 26384149)
49. Harris, A., Yang, X., Hegmans, A., Povirk, L., Ryan, J., Kelland, L., and Farrell, N. (2005) Synthesis, characterization, and cytotoxicity of a novel highly charged trinuclear platinum compound. Enhancement of cellular uptake with charge. Inorg. Chem. 44, 9598-9600.
50. Elferink, F., van der Vijgh, W. J., ten Bokkel Huinink, W. W., Vermorken, J. B., Klein, I., Winograd, B., Knobf, M. K., Simonetti, G., Gall, H. E., and McVie, J. G. (1987) Pharmacokinetics of ethylenediaminemalonatoplatinum(II) (JM-40) during phase I trial. Br. J. Cancer 56, 479-483.
51. Hydes, P. C., and Russell, M. J. H. (1988) Advances in platinum cancer chemotherapy. Advances in the design of cisplatin analogs. Cancer Metastasis Rev. 7, 67-89.
52. Cullen, K. J., Yang, Z., Schumaker, L., and Guo, Z. (2007) Mitochondria as a critical target of the chemotheraputic agent cisplatin in head and neck cancer. J. Bioenerg. Biomembr. 39, 43-50. (Pubitemid 46877172)
53. Singh, S., Chhipa, R. R., Vijayakumar, M. V., and Bhat, M. K. (2006) DNA damaging drugs-induced down-regulation of Bcl-2 is essential for induction of apoptosis in high-risk HPV-positive HEp-2 and KB cells. Cancer Lett. 236, 213-221. (Pubitemid 43732548)
54. Kumar, s., and Lavin, M. F. (1996) The ICE family of cysteine proteases as effectors of cell death. Cell Death Differ. 3, 255-267.
55. Chaoui, D., Faussat, A.-M., Majdak, P., Tang, R., Perrot, J.-Y., Pasco, S., Klein, C., Marie, J.-P., and Legrand, O. (2006) JC-1, a sensitive probe for a simultaneous detection of P-glycoprotein activity and apoptosis in leukemic cells. Cytometry, Part B 70, 189-196.
56. Cepeda, V., Fuertes, M. A., Castilla, J., Alonso, C., Quevedo, C., and Pérez, J. M. (2007) Biochemical mechanisms of cisplatin cytotoxicity. Anti-Cancer Agents Med. Chem. 7, 3-18.
57. Fichtinger-Schepman, A. M. J., Van der Veer, J. L., Den Hartog, J. H. J., Lohman, P. H. M., and Reedijk, J. (1985) Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. Biochemistry 24, 707-713.
58. Eastman, A. (1986) Reevaluation of interaction of cis- dichloro(ethylenediamine)platinum(II) with DNA. Biochemistry 25, 3912-3915.
59. 2] and DNA in vitro. J. Am. Chem. Soc. 107, 6376-6380.
60. Erickson, L. C., Zwelling, L. A., Ducore, J. M., Sharkey, N. A., and Kohn, K. W. (1981) Differential cytotoxicity and DNA crosslinking in normal and transformed human fibroblasts treated with cis-diamminedichloroplatinum(II). Cancer Res. 41, 2791-2794.
61. Strandberg, M. C., Bresnick, E., and Eastman, A. (1982) The significance of DNA crosslinking to cis-diamminedichloroplatinum(II)-induced cytotoxicity in sensitive and resistant lines of murine leukemia L1210 cells. Chem.-Biol. Interact. 39, 169-180. (Pubitemid 12190613)
62. Dijt, F. J., Fichtinger-Schepman, A. M. J., Berends, F., and Reedijk, J. (1988) Formation and repair of cisplatin-induced adducts to DNA in cultured normal and repair-deficient human fibroblasts. Cancer Res. 48, 6058-6062. (Pubitemid 18266801)
63. Kroemer, G., Zamzami, N., and Susin, S. A. (1997) Mitochondrial control of apoptosis. Immunol. Today 18, 44-51.
64. Shimizu, S., Eguchi, Y., Kamiike, W., Waguri, S., Uchiyama, Y., Matsuda, H., and Tsujimoto, Y. (1996) Bcl-2 blocks loss of mitochondrial membrane potential while ICE inhibitors act at a different step during inhibition of death induced by respiratory chain inhibitors. Oncogene 13, 21-29. (Pubitemid 26248541)
65. Ly, J. D., Grubb, D. R., and Lawen, A. (2003) The mitochondrial membrane potential (Delta ym) in apoptosis; an update. Apoptosis 8, 115-128.
66. Pasini, A., and Zunino, F. (1987) New cisplatin analogs: on the way to better carcinostatics. Angew. Chem. 99, 632-641. (Pubitemid 17125929)
67. Reedijk, J., Fichtinger-Schepman, A. M. J., Van Oosterom, A. T., and Van de Putte, P. (1987) Platinum amine coordination compounds as anti-tumor drugs. Molecular aspects of the mechanism of action. Struct. Bonding (Berlin, Ger.) 67, 53-89.